GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (LTS:0ABR) » Definitions » Current Accrued Expense

H. Lundbeck AS (LTS:0ABR) Current Accrued Expense : kr0 Mil (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS Current Accrued Expense?

H. Lundbeck AS's Current Accrued Expense for the quarter that ended in Sep. 2024 was kr0 Mil.

H. Lundbeck AS Current Accrued Expense Historical Data

The historical data trend for H. Lundbeck AS's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

H. Lundbeck AS Current Accrued Expense Chart

H. Lundbeck AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

H. Lundbeck AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

H. Lundbeck AS Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

H. Lundbeck AS Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of H. Lundbeck AS's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

H. Lundbeck AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (LTS:0ABR) » Definitions » Current Accrued Expense
Comparable Companies
OCSE:STENO ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XTAE:TEVA XSWX:SDZ NSE:DIVISLAB HKSE:03692 SZSE:000538 NSE:TORNTPHARM VTRS BOM:500124 BOM:532321 TSE:4507 BOM:543904 BOM:500257 NBIX
Traded in Other Exchanges
HLBBF:USA HLUBF:USA HLUNBc:UK 0ND5:UK HLUN A:Denmark HLUN B:Denmark LDBB:Germany LUNB:Austria
Address
Ottiliavej 9, Valby, DNK, 2500
Website
https://www.lundbeck.com
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.

H. Lundbeck AS Headlines

No Headlines